{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:36:03Z","timestamp":1787963763643,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002977","name":"Dalhousie University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.japh.2024.102299","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:56:09Z","timestamp":1733187369000},"page":"102299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The effect of out-of-pocket costs on medications for opioid use disorder and overdose: A scoping review"],"prefix":"10.1016","volume":"65","author":[{"given":"Ronald","family":"Watema-Lord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiranjeev","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2024.102299_bib1","article-title":"Opioid crisis: addiction, overprescription, and insufficient primary prevention","volume":"23","author":"Health-Americas","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"3","key":"10.1016\/j.japh.2024.102299_bib3","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.japh.2020.11.006","article-title":"Economic burden of opioid crisis and the role of pharmacist-led interventions","volume":"61","author":"Sanyal","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2024.102299_bib6","series-title":"StatPearls","article-title":"Opioid addiction","author":"Azadfard","year":"2023"},{"key":"10.1016\/j.japh.2024.102299_bib7","series-title":"StatPearls","article-title":"Opioid overdose","author":"Schiller","year":"2024"},{"key":"10.1016\/j.japh.2024.102299_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.japh.2024.102299_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.22374\/cjgim.v16i2.425","article-title":"Opioid use disorder: screening, diagnosis, and management","volume":"16","author":"Randhawa","year":"2021","journal-title":"Can J Gen Int Med"},{"key":"10.1016\/j.japh.2024.102299_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.038","article-title":"Impact of a community-based naloxone distribution program on opioid overdose death rates","volume":"204","author":"Naumann","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.japh.2024.102299_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1715163520958435","article-title":"The status of naloxone in community pharmacies across Canada","volume":"153","author":"So","year":"2020","journal-title":"Can Pharm J"},{"key":"10.1016\/j.japh.2024.102299_bib13","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.japh.2024.102299_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.japh.2024.102299_bib16","doi-asserted-by":"crossref","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.japh.2024.102299_bib17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1176\/appi.ps.201900309","article-title":"Early discontinuation of buprenorphine therapy for opioid Use disorder among privately insured adults","volume":"71","author":"Agbese","year":"2020","journal-title":"Psychiatr Serv"},{"issue":"7","key":"10.1016\/j.japh.2024.102299_bib18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40264-020-00923-6","article-title":"Rates and costs of dispensing naloxone to patients at high risk for opioid overdose in the United States, 2014-2018","volume":"43","author":"Barenie","year":"2020","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.japh.2024.102299_bib19","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hec.4255","article-title":"The effect of British Columbia's Pharmacare coverage expansion for opioid agonist treatment","volume":"30","author":"Hongdilokkul","year":"2021","journal-title":"Health Econ"},{"issue":"8","key":"10.1016\/j.japh.2024.102299_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2663","article-title":"Trends in out-of-pocket costs for naloxone by drug brand and payer in the US, 2010-2018","volume":"3","author":"Peet","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.japh.2024.102299_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106820","article-title":"Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018","volume":"153","author":"Dunphy","year":"2021","journal-title":"Prev Med"},{"issue":"3","key":"10.1016\/j.japh.2024.102299_bib22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MLR.0000000000001689","article-title":"Variation in initiation, engagement, and retention on medications for opioid use disorder based on health insurance plan design","volume":"60","author":"Morgan","year":"2022","journal-title":"Med Care"},{"key":"10.1016\/j.japh.2024.102299_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103472","article-title":"Economic analysis of out-of-pocket costs among people in opioid agonist treatment: a cross-sectional survey in three Australian jurisdictions","volume":"99","author":"Tran","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"9","key":"10.1016\/j.japh.2024.102299_bib24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamainternmed.2023.2826","article-title":"Buprenorphine out-of-pocket costs and discontinuation in privately insured adults with opioid use disorder","volume":"183","author":"Leech","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.japh.2024.102299_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54590","article-title":"Trends in out-of-pocket costs for and characteristics of pharmacy-dispensed buprenorphine medications for opioid use disorder treatment by type of payer, 2015 to 2020","volume":"6","author":"Strahan","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.japh.2024.102299_bib26","article-title":"Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: findings from a national commercially insured cohort","volume":"159","author":"McCann","year":"2024","journal-title":"J\u00a0Subst Use Addict Treat"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124003303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124003303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T13:16:37Z","timestamp":1739798197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124003303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1544319124003303"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.102299","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of out-of-pocket costs on medications for opioid use disorder and overdose: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.102299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102299"}}